Literature DB >> 16317094

Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction.

Katharina Fleischhauer1, Franco Locatelli, Marco Zecca, Maria Grazia Orofino, Claudio Giardini, Piero De Stefano, Andrea Pession, Angela Maria Iannone, Carlo Carcassi, Elisabetta Zino, Giorgio La Nasa.   

Abstract

The success of allogeneic hematopoietic stem cell transplantation (HSCT) from matched unrelated donors (UDs) for beta-thalassemia may be hampered by the occurrence of graft rejection. Here, we show that the rate of this complication can be reduced by selecting 5-loci HLA-matched donors without nonpermissive mismatches at HLA-DPB1, defined according to an algorithm previously described and based on principles of central T-cell tolerance. Seventy-two consecutive patients and their UDs, prospectively selected for matching at the allelic level for HLA-A, -B, -C, -DRB, and -DQB1 loci, were enrolled in the analysis. These pairs were either DPB1 matched/permissively mismatched (n = 45, control group) or had at least one nonpermissive DPB1 mismatch in the host-versus-graft (HvG; n = 17) or in the graft-versus-host (GvH; n = 10) direction. In multivariate analysis, the risk of rejection was significantly increased in the group with HvG disparity (RR = 7.42; 95% CI = 1.29-42.68; P = .02) as compared to the control group. A lower, statistically significant, probability of thalassemia-free survival was found in patients belonging to the HvG group as compared to controls (RR = 5.15; 95% CI = 1.58-16.82; P = .01). These data suggest that in patients with thalassemia, the incidence of graft failure after HSCT may be reduced by appropriate selection of UDs, with such selection taking into account the functional rules of immunogenetics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16317094     DOI: 10.1182/blood-2005-08-3374

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

Review 1.  Genetics of graft-versus-host disease: the major histocompatibility complex.

Authors:  Effie W Petersdorf
Journal:  Blood Rev       Date:  2012-11-20       Impact factor: 8.250

2.  Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).

Authors:  Naynesh R Kamani; Mark C Walters; Shelly Carter; Victor Aquino; Joel A Brochstein; Sonali Chaudhury; Mary Eapen; Brian M Freed; Michael Grimley; John E Levine; Brent Logan; Theodore Moore; Julie Panepinto; Suhag Parikh; Michael A Pulsipher; Jane Sande; Kirk R Schultz; Stephen Spellman; Shalini Shenoy
Journal:  Biol Blood Marrow Transplant       Date:  2012-02-16       Impact factor: 5.742

3.  Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study.

Authors:  Katharina Fleischhauer; Bronwen E Shaw; Theodore Gooley; Mari Malkki; Peter Bardy; Jean-Denis Bignon; Valérie Dubois; Mary M Horowitz; J Alejandro Madrigal; Yasuo Morishima; Machteld Oudshoorn; Olle Ringden; Stephen Spellman; Andrea Velardi; Elisabetta Zino; Effie W Petersdorf
Journal:  Lancet Oncol       Date:  2012-02-15       Impact factor: 41.316

4.  Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders.

Authors:  John Horan; Tao Wang; Michael Haagenson; Stephen R Spellman; Jason Dehn; Mary Eapen; Haydar Frangoul; Vikas Gupta; Gregory A Hale; Carolyn K Hurley; Susana Marino; Machteld Oudshoorn; Vijay Reddy; Peter Shaw; Stephanie J Lee; Ann Woolfrey
Journal:  Blood       Date:  2012-07-24       Impact factor: 22.113

5.  Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation.

Authors:  Stefan O Ciurea; Peter F Thall; Xuemei Wang; Sa A Wang; Ying Hu; Pedro Cano; Fleur Aung; Gabriela Rondon; Jeffrey J Molldrem; Martin Korbling; Elizabeth J Shpall; Marcos de Lima; Richard E Champlin; Marcelo Fernandez-Vina
Journal:  Blood       Date:  2011-10-03       Impact factor: 22.113

Review 6.  Gene therapy for hemoglobinopathies: the state of the field and the future.

Authors:  Shanmuganathan Chandrakasan; Punam Malik
Journal:  Hematol Oncol Clin North Am       Date:  2014-04       Impact factor: 3.722

7.  A trial of unrelated donor marrow transplantation for children with severe sickle cell disease.

Authors:  Shalini Shenoy; Mary Eapen; Julie A Panepinto; Brent R Logan; Juan Wu; Allistair Abraham; Joel Brochstein; Sonali Chaudhury; Kamar Godder; Ann E Haight; Kimberly A Kasow; Kathryn Leung; Martin Andreansky; Monica Bhatia; Jignesh Dalal; Hilary Haines; Jennifer Jaroscak; Hillard M Lazarus; John E Levine; Lakshmanan Krishnamurti; David Margolis; Gail C Megason; Lolie C Yu; Michael A Pulsipher; Iris Gersten; Nancy DiFronzo; Mary M Horowitz; Mark C Walters; Naynesh Kamani
Journal:  Blood       Date:  2016-09-13       Impact factor: 22.113

Review 8.  Optimal HLA matching in hematopoietic cell transplantation.

Authors:  Effie W Petersdorf
Journal:  Curr Opin Immunol       Date:  2008-08-08       Impact factor: 7.486

9.  Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study.

Authors:  A A Hamidieh; M Behfar; Z Pourpak; S Faghihi-Kashani; M R Fazlollahi; A S Hosseini; M Movahedi; M Mozafari; M Moin; A Ghavamzadeh
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

10.  Menstrual blood cells display stem cell-like phenotypic markers and exert neuroprotection following transplantation in experimental stroke.

Authors:  Cesar V Borlongan; Yuji Kaneko; Mina Maki; Seong-Jin Yu; Mohammed Ali; Julie G Allickson; Cyndy D Sanberg; Nicole Kuzmin-Nichols; Paul R Sanberg
Journal:  Stem Cells Dev       Date:  2010-04       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.